Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Porteus, Matthew, MD
Modality
other_biological
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04784052CT.gov Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab | — | Recruiting | — | — | — |
NCT03600909CT.gov A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | — | Terminated | — | — | — |
NCT02143830CT.gov HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | — | Recruiting | — | — | — |
NCT00258427CT.gov Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia | — | Completed | — | — | — |
NCT00053989CT.gov NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fanconi Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit (this asset) | Porteus, Matthew, MD | P2 | BB · 69 |
| Cyclophosphamide | Porteus, Matthew, MD | P2/3 | BBB |
| Fludarabine | Porteus, Matthew, MD | P2/3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Nivestim | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Prednisone | Fred Hutchinson Cancer Center | P2 | BB |
| Plerixafor | Assistance Publique - Hôpitaux de Paris | P2 | BB |
| Alemtuzumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2/3 | BB |
+34 more in the Fanconi Anemia cohort
Other indications for Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 75 |
| Plasma Cell Myeloma | — | P4 | BBB · 72 |
| Myeloproliferative Neoplasm | — | P2/3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Human T-Lymphocyte Immunoglobulin, Rabbit in Fanconi Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-human-t-lymphocyte-immunoglobulin-rabbit-fanconi-anemia-118989
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →